Navigation Links
Echo Therapeutics To Present at Prestigious 'Innovations in Diabetes' Conference
Date:7/9/2009

FRANKLIN, Mass., July 9 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system, announced today that Patrick T. Mooney, M.D., Chairman and Chief Executive Officer, will present at the "Innovations in Diabetes" Conference on, Tuesday, July 14, 2009 at 5:30 pm ET. The presentation will occur live and will be held at The Pier V Hotel at the Inner Harbor in Baltimore.

"We are honored to have been selected to present at this prestigious conference which highlights cutting edge technologies in the field of diabetes management," stated Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. "We look forward to introducing Symphony, our needle-free, continuous glucose monitoring technology, to the large audience of physician thought-leaders from around the world who will be attending the conference, and to providing an update on our notable progress toward our goal of making Symphony available to physicians and patients in early 2010."

About Echo Therapeutics

Echo Therapeutics is focused on medical devices and specialty pharmaceuticals. Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude(TM) SkinPrep System for transdermal drug delivery of a wide range of novel topical reformulations of widely-used, FDA-approved products.

About Innovara

Innovara, Inc. is a global strategic consulting, educational development, and business development corporation specializing in forming unique alliances between MDs and medical institutions involved in medical research and education, with the aim of aiding advancing medical education, disease management and patient care worldwide. Innovara was founded over 25 years ago and is dedicated to working with globally recognized medical institutions, physicians, health care and other professionals, bringing the "latest from the best" in medical education and advances in research to physicians and other healthcare professionals around the world. For more information contact: Margot DeFrance, Executive Vice President Business Development, margot.defrance@innovara.com.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the efficacy of Echo's Symphony tCGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM System, the ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's ability to develop, market and sell diagnostic products based on its skin permeation platform technologies, including the Symphony tCGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2008, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo Therapeutics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements.

    10 Forge Parkway
    Franklin, MA 02038, USA
    Tel: 1+ 877-476-6878
    Fax: 1+ 508-553-8760
    www.echotx.com


    For More Information:
    Patrick T. Mooney, MD
    Chairman and Chief Executive Officer
    (508)-530-0329


'/>"/>
SOURCE Echo Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of Wnt Pathway
2. New Report Just Published: World Multiple Myeloma Therapeutics Market Report
3. New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report
4. Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
5. European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application
6. Fate Therapeutics Granted Exclusive License By The Regents of the University of California to Stem Cell Modulators for Osteo-Regeneration
7. Hyperion Therapeutics Raises $60 Million Series C
8. Cornerstone Therapeutics Joins the Russell 3000(R) Index
9. Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts
10. Intrinsic Therapeutics Barricaid and Magellan Spine Technologies DART to Drive European Annulus Repair Market
11. Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... MAP ... the risk of relapse in people with addiction who are served by MAP’s ... in the market through empowering patients to stay connected with their entire support ...
(Date:3/30/2017)... (PRWEB) , ... March 30, 2017 , ... Although many ... concerns, equally as many are wary of baring their skin for other reasons, including ... at West Dermatology can help get the skin prepared for the summer weather and ...
(Date:3/30/2017)... , ... March 30, 2017 , ... A new ... that following joint replacement surgery – the best place for a patient to recover ... they are in familiar surroundings and have ample opportunity to rest and recover naturally,” ...
(Date:3/30/2017)... ... 2017 , ... According to the American Society of Plastic Surgeons (ASPS), over ... top 5 most popular minimally-invasive cosmetic procedures in the country. With summer close, it’s ... the next 8-10 weeks. For anyone considering a hair removal procedure, there are a ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... its educational offerings of corporate finance programs to address the increasingly complex educational ... help executives increase their knowledge of sophisticated corporate finance and will increase their ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... -- P rogressed to commercial ... Vergenix™STR distribution and sales agreements in Europe ... 3D bioInk , the Company , s ... for 3D printing of human organs and tissue   P ... in specific indications in 2017   CollPlant (TASE: ...
(Date:3/30/2017)... 30, 2017  Boston Scientific Corporation (NYSE: ... Symetis SA, a privately-held Swiss structural heart company focused ... million in up-front cash. The Symetis portfolio includes ... * systems for use in the treatment of ... stenosis, which are sold in Europe ...
(Date:3/30/2017)... , March 30, 2017 Stock-Callers.com ... in the research, development, and production of non-electronic medical, surgical, ... are: Endologix Inc. (NASDAQ: ELGX), Becton, Dickinson and Co. (NYSE: ... Inc. (NYSE: BCR ). Download the free research ... ...
Breaking Medicine Technology: